Bone mineral density and fractures in older men with chronic obstructive pulmonary disease or asthma by Dam, T.-T. et al.
ORIGINAL ARTICLE
Bone mineral density and fractures in older men
with chronic obstructive pulmonary disease or asthma
T.-T. Dam & S. Harrison & H. A. Fink & J. Ramsdell &
E. Barrett-Connor &
for the Osteoporotic Fractures in Men (MrOS) Research Group
Received: 22 September 2008 /Accepted: 26 August 2009 /Published online: 9 October 2009
# The Author(s) 2009. This article is published with open access at Springerlink.com
Abstract
Summary In 5,541 community dwelling men, chronic ob-
structive pulmonary disease, or asthma was associated with
lower bone mineral density (BMD) at the spine and total
hip and an increased risk of vertebral and nonvertebral
fractures independent of age, body mass index, and smok-
ing. Men prescribed with corticosteroids had the lowest
BMD.
Introduction It is unclear whether chronic obstructive
pulmonary disease (COPD) is independently associated
with BMD and fractures.
Methods In 5,541 men from the Osteoporotic Fractures in
Men Study, history of COPD or asthma, current treatment
with corticosteroids, BMD, bone loss after 4.5 years and
fractures were ascertained.
Results Seven hundred fourteen (13%) men reported
COPD or asthma, of which 103 were prescribed an oral
steroid and 177 an inhaled steroid. Independent of con-
founders, men prescribed corticosteroids for COPD or
asthma had the lowest BMD and a 2-fold increased risk
of vertebral osteoporosis compared to men with no history
of COPD or asthma (OR 2.13, 95% CI (confidence
interval) 1.15–3.93 oral steroids; OR 2.05, 95% CI 1.27–
3.31 inhaled steroids). During follow-up, BMD increased at
the spine, but there was no difference in bone loss at the
hip. However, men with COPD or asthma had a 2.6- and
1.4-fold increased risk of vertebral and nonvertebral
fractures, respectively.
Conclusion Chronic obstructive pulmonary disease or
asthma was associated with lower BMD at the spine and
hip and increased risk of vertebral and nonvertebral
fractures independent of age, clinic site, BMI, and smoking.
A history of COPD or asthma may be a useful clinical risk
factor to identify patients with osteoporosis.
Keywords Boneloss.Bonemineraldensity.Elderly.
Fractures.Pulmonary disease
Introduction
The National Heart Lung Blood Institute reports that an
estimated 16 million adults are diagnosed with chronic
obstructive pulmonary disease (COPD). Mainly caused by
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DOI 10.1007/s00198-009-1076-xcigarette smoking, COPD was the fourth leading cause of
death in older adults in 2004 [1]. By 2020, COPD is
projected to be the third leading cause of death for both
men and women. Among the comorbidities associated with
COPD, osteoporosis is believed to affect 36% to 60% of
patients with chronic lung disease [2–4]. The prevalence of
osteoporosis and the risk of fractures increase with worsen-
ing airflow obstruction.
The relationship between obstructive pulmonary disease
and osteoporosis is complicated. Both osteoporosis and
COPD share some common risk factors. It is unclear
whether the associations between COPD or asthma and
osteoporosis is independently related to poor pulmonary
function or to the effects of related attributes such as
smoking, corticosteroids, low body weight, poor nutrition,
and physical inactivity. The objective of the present study is
to evaluate whether a history of COPD or asthma is an
independent risk factor for low bone mineral density, bone
loss, and fractures in older men.
Methods
Participants
From March 2000 to April 2002, the Osteoporotic Fractures
in Men Study (MrOS) recruited 5,995 ambulatory commu-
nity dwelling men aged 65 years or older at six clinical
centers in the United States (Birmingham, Alabama;
Minneapolis, Minnesota; Palo Alto, California; Mononga-
hela Valley near Pittsburgh, Pennsylvania; Portland, Ore-
gon; and San Diego, California). Men without bilateral hip
replacements who were able to ambulate without the
assistance of another person and were able to provide
informed consent were recruited. Further details of the
MrOS cohort, protocol, and recruitment have been pub-
lished [5, 6]. The institutional review boards at all
participating centers approved the study protocol.
Of 5,995 men enrolled in MrOS, 454 were excluded
from all analyses either due to missing baseline bone
density measurements (N=10), missing baseline medication
inventory forms (N=343), or baseline use of osteoporosis
medications (N=101), leaving 5,541 men for the cross-
sectional analyses. Of these men, 4,147 (75%) returned for
the second clinic visit and had repeated BMD measure-
ments between December 2003 and April 2006, an average
of 4.5 years later (range 3.5–5.9 years). These men
comprised the participants in the longitudinal analyses.
Among the men who were not included in the longitudinal
analyses, 34 attended visit 2 but did not have repeat BMD
measurements, 657 returned only the mailed questionnaire,
517 had died, 106 refused, and 80 left the cohort for various
reasons, including poor health, participants moving away,
being too busy, or loss of interest.
Covariates
At baseline, all participants completed a self-administered
questionnaire, which included age, race/ethnicity, education
level, marital status, personal medical history, and self-
reported health and smoking history. Subjects were asked
“Have you smoked at least 100 cigarettes (five packs) in
your entire life?” Participants who answered “yes” were
then asked the average number of cigarettes smoked per
day and the number of years. The number of smoking packs
per year was calculated and used for these analyses. The
physical activity scale for the elderly (PASE) was used to
assess physical activity level [7]. Participants were asked to
bring in all prescription medications used within the last
30 days. All prescription medications were recorded in an
electronic medications inventory database (San Francisco
Coordinating Center, San Francisco, California, USA).
Each medication was matched to its ingredient(s) based
on the Iowa Drug Information Service (IDIS) Drug
Vocabulary (College of Pharmacy, University of Iowa,
Iowa City, Iowa, USA). Medications related to COPD or
asthma were adjudicated and categorized as: (1) oral
corticosteroids; (2) inhaled corticosteroids; (3) beta ago-
nists/anticholinergics; and (4) other, which included mast
cell stabilizers and leukotriene inhibitors. Height (cm) was
measured on Harpenden stadiometers, and weight (kg) was
measured on standard balance beam or digital scales using
standard protocols. Body mass index (BMI) was calculated
as weight divided by height (kg/m
2).
Ascertainment of pulmonary disease
At the baseline visit, all participants were asked, “Has a
doctor or other healthcare provider ever told you that you
had or have chronic obstructive lung disease, chronic
bronchitis, asthma, or chronic COPD?” If “yes,” partic-
ipants were asked, “Are you currently being treated for this
condition by a doctor?” Participants were categorized based
on their response to these two questions and by review of
the medication inventory form. There were 4,827 men who
did not report a history of COPD or asthma and were not
prescribed any medications indicated for COPD or asthma.
Of the 714 men who were identified as having COPD or
asthma, 434 were not prescribed corticosteroids, 103 were
prescribed an oral steroid, and 177 were prescribed inhaled
corticosteroid. There were 16 men who were prescribed
both an oral and inhaled corticosteroid, and they were
grouped with the men who were taking oral steroids only.
Duration of lung disease or corticosteroid treatment was not
obtained.
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Bone mineral density was measured at the lumbar spine,
total hip, and hip subregions using dual energy X-ray
absorptiometry (DXA; QDR 4500W, Hologic, Inc., Wal-
tham, Massachusetts, USA). Lumbar spine BMD for each
subject was measured in the anterior–posterior projection
and calculated as the mean of the BMD from the first
through fourth lumbar vertebrae. All measurements of
hip DXA BMD were made on the right hip, unless, the
subject reported a right hip replacement or metal objects
in the right leg in which case the left hip was measured.
Repeat BMD were measured using the same DXA
machines and methodology employed at visit 1. The
percent BMD change was determined by subtracting
BMD at the baseline from BMD at the follow-up visit
divided by baseline BMD and was expressed as an
annualized percentage of the baseline value (percent/
year).
A central quality control lab, certification of DXA
operators, and standardized procedures for scanning were
used to insure reproducibility of DXA measurements. At
baseline, a set of spine, hip, and linearity phantoms were
circulated and measured at the six clinical sites. The
variability across clinics was within acceptable limits, and
cross calibration correction factors were not required. To
adjust for interclinic differences, statistical models in-
clude indicator variable for the individual scanners. Each
clinic scanned a spine and hip phantom throughout the
study to monitor longitudinal changes, and correction
factors were applied to participant data as appropriate.
The precision of DXA scans of the spine and hip is 1–
2% [8].
Using normative data for young adult white males, BMD
was categorized as normal, low bone mineral density, or
osteoporosis, as defined by the World Health Organization
[9, 10]. To calculate hip and femoral neck T-scores, mean,
and SD reference values from NHANES III were used [11].
For the spine T-scores , mean and SD reference values from
the Hologic database were used. Participants with a T-score
≤−2.5 SD were categorized as having osteoporosis.
Fractures
After the baseline examination, participants were contacted
about fractures every 4 months by postcard or telephone.
The response rate to these questionnaires exceeded 99% in
surviving men. Vertebral fractures were diagnosed clinical-
ly. Fractures were adjudicated centrally by physician review
of medical records and X-ray reports. Unconfirmed and
pathologic fractures were not included in the analyses.
The mean follow-up time for incident fractures was
6.1 years.
Statistical analysis
Participant baseline characteristics were compared by
COPD or asthma status using chi-square tests for categor-
ical variables and analysis of variance for continuous
variables. Least squared means linear regression models
were used to examine the association between COPD or
asthma status and BMD; cross-sectional results were
expressed as mean BMD with corresponding 95% confi-
dence intervals (CI) and longitudinal results were expressed
as mean annualized percent BMD change with correspond-
ing 95% CI. Logistic regression was used to assess the
association between COPD or asthma status and osteopo-
rosis risk; Cox proportional hazards models were used to
assess the association between COPD or asthma status and
fracture outcomes. Results were expressed as odds ratios
and hazard ratios, respectively, with corresponding 95% CI.
To control for confounding by corticosteroid use, COPD or
asthma was stratified by oral or inhaled corticosteroid use.
Therefore, the predictor variable was categorized into four
groups: (1) No COPD or asthma; (2) COPD or asthma, no
steroids; (3) COPD or asthma, oral steroids; and (4) COPD
or asthma, inhaled steroids. Known or suspected confound-
ers of the relationship between pulmonary disease and
BMD including age, BMI, ethnicity, smoking (packs per
year), calcium or vitamin D supplement use, clinic site,
hypertension, coronary artery disease, diabetes mellitus,
stroke, self-reported health status, physical activity level,
and alcohol were examined as potential covariates.
Covariates were added to the multivariate models if the
p value was <0.10 in age-adjusted analysis. Model 1
demonstrates the parsimonious model adjusting for age,
BMI, clinic, and smoking; Model 2 is adjusted for all
possible confounders. All analyses were performed using
SAS software, version 9.1 (SAS Institute, Cary, North
Carolina, USA).
Results
Participant characteristics
Of the 5,541 MrOS participants, 714 (13%) men were
categorized as having COPD or asthma, of whom 280 were
currently prescribed an inhaled and/or oral corticosteroid.
Of the 280 men, 177 (63%) were prescribed inhaled
corticosteroid, 87 (31%) were prescribed oral cortico-
steroid, and 16 (6%) were prescribed both inhaled and oral
corticosteroid. Of these 280 men, 165 (59%) were also
prescribed other COPD or asthma medications like a beta
agonist, anticholinergic, mast cell stabilizer, and/or leuco-
triene inhibitors. For the other 434 men categorized as
COPD or asthma, not on steroids, 108 (25%) were
Osteoporos Int (2010) 21:1341–1349 1343prescribed a beta agonist, anticholinergic, mast cell stabl-
izer, and/or leucotriene inhibitors.
Participant characteristics are presented in Table 1.
Compared to men without COPD or asthma, men with
COPD or asthma were older, less physically active, and
reported poorer health status with more medical conditions,
including hypertension, coronary artery disease, and stroke.
Men who were taking oral steroids for COPD or asthma
were older, less physically active, reported poorer health,
and had more strokes and coronary artery disease. These
men also had the heaviest smoking history, although, only
3% were currently smoking.
Oral corticosteroid use, smoking, decreased physical
activity, self-reported fair/poor/very poor health, a history
of stroke, and a history of coronary artery disease were
independently associated with COPD or asthma in age-
adjusted logistic regression models. Men who were pre-
scribed oral corticosteroids were almost four times more
likely to report a physician diagnosis of COPD or asthma
(OR 3.88 (95% CI 2.66–5.64)).
Association of COPD or asthma with BMD
In models adjusting for age, clinic site, BMI, and smoking,
men with COPD or asthma had lower BMD at total hip,
femoral neck, and spine compared to men who did not have
COPD or asthma. Men who were taking oral or inhaled
corticosteroids had lower BMD at the spine and hip, a
difference between 0.02 to 0.05 g/cm
2 (Table 2). Adjust-
ment for self-reported health, alcohol, calcium supplement,
physical activity, coronary artery disease, stroke, and
diabetes did not change the results.
Men with COPD or asthma not prescribed cortico-
steroids did not have an increased risk of osteoporosis at
the hip, femoral neck, or spine after adjusting for
confounders. However, men prescribed oral or inhaled
corticosteroids had a 2-fold increased odds of osteoporosis
at the spine in age-adjusted models (OR 2.13, 95% CI
1.15–3.93 for oral steroids; OR 2.05, 95% CI 1.27–3.31 for
inhaled steroids). Additional adjustment for confounders
attenuated the results, but oral steroid users still had a 91%
increased risk of osteoporosis at the spine (OR 1.91, 95%
CI 1.02–3.58), and inhaled steroid user had a 71%
increased risk of osteoporosis at the spine (OR 1.71, 95%
CI 1.04–2.81). Osteoporosis risk at the total hip and
femoral neck were not statistically significant after multi-
variate adjustment (Table 3).
Association of COPD or asthma with bone loss
After 4.6 years of follow-up, there was no difference in the
annual rate of bone loss at the total hip or femoral neck
between men with or without COPD or asthma. However,
spine BMD increased in all men. This is likely due to
increased osteophyte formation from osteoarthritis (Table 4).
Association of COPD or asthma with incident fractures
Men with COPD or asthma had a 3-fold increased risk for
incident clinical vertebral fractures compared to men who
did not have COPD or asthma (OR 3.17, 95% CI 1.93–
5.20). The magnitude of the association with vertebral
fractures decreased slightly after adjusting for confounders
(OR 2.64, 95% CI 1.57–4.44). In the group of men with
COPD or asthma, taking inhaled corticosteroids, the risk for
incident vertebral fractures was elevated almost 2-fold (OR
1.86, 95% CI 0.80–4.32; Table 5). This, however, did not
meet statistical significance.
Men with COPD or asthma did not have an increased
risk of hip fractures. Although men with COPD or asthma
had a 12% increased risk of hip fractures (OR 1.12, 95% CI
0.55, 2.26), the OR included one and did not meet
statistical significance. In men using oral or inhaled steroids
for COPD or asthma, the results were similar.
Finally, men with COPD or asthma had a 42% increased
risk of incident nonvertebral fractures (OR 1.42, 95% CI
1.03–1.96). Men taking oral or inhaled steroids, however,
did not have an increased risk of incident nonvertebral
fractures.
Discussion
In this cohort of community dwelling older men, COPD or
asthma was associated with lower BMD at the total spine,
total hip, and femoral neck, but was not associated with
increased bone loss 4.5 years later. However, men with
COPD or asthma had a 2.6-fold increased risk of clinical
vertebral fractures and a 1.4-fold increased risk of non-
vertebral fractures approximately 6 years later. Additional-
ly, men who were prescribed with inhaled or oral
corticosteroids for COPD or asthma had lower BMD at all
three sites and nearly a 2-fold increased risk of osteoporosis
at the spine.
Previously published clinic-based studies suggest that
30–50% of all pulmonary disease patients (including
subjects with COPD, cystic fibrosis, idiopathic pulmonary
fibrosis, and those waiting on the transplant list) have
osteoporosis at the spine or femoral neck [2, 4]. In another
study, patients with chronic lung disease were found to
have a 5-fold increased risk of hip or spine osteoporosis
compared to controls; the risk increased to 9-fold if taking
steroids [3]. Three cross-sectional observational studies
have described an independent association between osteo-
porosis with poor pulmonary function (measured as forced
1344 Osteoporos Int (2010) 21:1341–1349expiratory volume in 1 second, FEV1)[ 12–14]. In these
studies, BMD decreased approximately 0.02 g/cm
2 for
every 1 L per second decrease in FEV1 and had a 2.4
increased risk of osteoporosis. Fractures have been docu-
mented in 29% of COPD and 25% of cystic fibrosis
patients [4]. Vestegaard and colleagues found that chronic
lung diseases like COPD and emphysema were associated
with a 1.2- to 1.3-fold higher risk of fractures [15]. Inhaled
Table 1 Baseline characteristics for men in the osteoporotic fractures in men study (MrOS) by chronic obstructive pulmonary disease or asthma status
No COPD
or asthma
(N=4827)
COPD or asthma,
no steroids
(N=434)
COPD or asthma,
oral steroids
(N=103)
COPD or asthma,
inhaled steroids
(N=177)
p value
Age (years)±SD 73.5±5.9 74.1±5.9 74.3±5.6 74.7±5.5 0.002
Race (%)
White 89.0 91.0 87.4 87.0 0.11
African-American 4.1 5.3 7.8 4.5
Asian 3.5 0.9 1.9 4.0
Hispanic 2.2 1.4 1.9 4.0
Other 1.2 1.4 1.0 0.5
BMI (kg/m2)±SD 27.4±3.8 27.7±4.3 27.2±3.6 26.9±4.1 0.17
Smoking (%)
Never 39.2 25.6 32.0 24.9 <0.0001
Past 57.5 69.6 65.1 71.8
Current 3.3 4.8 2.9 3.4
Number of packs per year (%)
0 39.5 25.8 32.0 24.9 <0.0001
>0–7 12.8 8.3 14.6 11.3
>7–29 25.3 23.0 21.4 24.3
>29 22.4 42.9 32.0 39.6
Alcohol drinks per week (%)
0 35.1 39.4 36.9 39.6 0.58
1–7 47.1 44.4 46.6 45.2
>7 17.8 16.2 16.5 15.3
Physical activity
a±SD 148.3±67.9 137.6±71.6 128.4±77.4 132.4±63.4 <0.0001
Self-reported health status (%)
Excellent/good 87.8 72.8 70.9 70.1 <0.0001
Fair/poor/very poor 12.2 27.2 29.1 29.9
Medical conditions (%)
Coronary artery disease 13.7 16.6 21.4 16.6 0.04
Diabetes mellitus 10.5 13.8 13.6 10.2 0.14
HTN 43.5 46.5 45.6 46.9 0.51
Stroke 5.3 6.9 10.7 7.3 0.04
Inhaled corticosteroid (%) −− 15.5 100.0 NA
Oral corticosteroid (%) −−100.0 − NA
Beta agonist and/or anticholinergic (%) − 21.7 17.5 80.2 <0.0001
Mast cell stabilizers and/or leucotriene agonist (%) − 5.5 5.8 19.2 <0.0001
Vitamin D supplement (%) 59.1 56.7 59.8 63.1 0.53
Calcium supplement (%) 65.1 63.4 68.6 69.9 0.42
BMD total spine (g/cm
2) 1.08±0.18 1.05±0.19 1.03±0.16 1.03±0.20 <0.0001
BMD total hip (g/cm
2) 0.96±0.14 0.94±0.14 0.92±0.13 0.93±0.15 <0.0001
BMD femoral neck (g/cm
2) 0.79±0.13 0.77±0.13 0.76±0.13 0.76±0.14 <0.0001
NA not available
aphysical activity scale elderly (PASE) score
Osteoporos Int (2010) 21:1341–1349 1345corticosteroids have also been associated with increased
fracture risk [16, 17].
In this cohort, men with a history of COPD or asthma
did not have increased annual rate of bone loss at the total
hip or femoral neck, but did have a 2.6-fold increase in
vertebral fractures independent of confounders. The ob-
served associations are likely underestimated in that they
were attenuated by the selective loss of older participants
with lower BMD levels, more lung disease, and poorer
physical function at baseline. Moreover, more men with
COPD or asthma died or did not participate at visit 2.
Although, we would have expected an increased risk of
Table 3 Likelihood of osteoporosis by chronic lung disease status
No COPD or asthma
(N=4827)
COPD or asthma,
no steroids (N=434)
COPD or asthma,
oral steroids (N=103)
COPD or asthma,
inhaled steroids (N=177)
Total spine (g/cm
2)
a
Age-adjusted 1.0 (referent) 0.99 (0.65–1.50) 2.13 (1.15–3.93) 2.05 (1.27–3.31)
Model 1
c 1.0 (referent) 0.99 (0.65–1.52) 2.11 (1.14–3.92) 1.93 (1.19–3.15)
Model 2
d 1.0 (referent) 0.93 (0.61–1.44) 1.91 (1.02–3.58) 1.71 (1.04–2.81)
Total hip (g/cm
2)
b
Age-adjusted 1.0 (referent) 1.41 (0.69–2.85) 2.69 (0.96–7.58) 1.86 (0.74–4.67)
Model 1
c 1.0 (referent) 1.17 (0.56–2.44) 2.27 (0.77–6.70) 1.29 (0.49–3.38)
Model 2
d 1.0 (referent) 1.08 (0.51–2.28) 2.08 (0.51–2.27) 1.07 (0.69–6.26)
Femoral neck (g/cm
2)
b
Age-adjusted 1.0 (referent) 1.59 (1.07–2.37) 1.79 (0.85–3.75) 1.36 (0.72–2.56)
Model 1
c 1.0 (referent) 1.41 (0.92–2.14) 1.65 (0.77–3.54) 1.06 (0.55–2.03)
Model 2
d 1.0 (referent) 1.29 (0.84–1.99) 1.32 (0.59–2.97) 0.95 (0.49–1.83)
aUsing normals for men (Hologic)
bUsing normals for men (NHANES)
cAdjusted for age, clinic, BMI, and smoking
dAdjusted for age, clinic, BMI, smoking, self-reported health, alcohol (drinks per week), calcium, PASE score, coronary artery disease, stroke,
and diabetes
Table 2 Age-adjusted and multivariate-adjusted
a mean (95% CI) bone mineral density by COPD or asthma and steroid status
No COPD or asthma
(N=4,827)
COPD or asthma,
no steroids
(N=434)
COPD or asthma,
oral steroids
(N=103)
COPD or asthma,
inhaled steroids
(N=177)
p trend
Total spine (g/cm
2)
Age-adjusted 1.08 (1.07–1.08) 1.05 (1.04–1.07)
* 1.02 (1.00–1.06)
* 1.02 (1.00–1.05)
* <0.0001
Model 1
a 1.08 (1.07–1.08) 1.05 (1.03–1.07)
* 1.03 (0.99–1.06)
* 1.03 (1.00–1.06)
* <0.0001
Model 2
b 1.08 (1.07–1.08) 1.05 (1.04–1.07)
* 1.03 (0.99–1.06)
* 1.03 (1.01–1.06)
* <0.0001
Total hip (g/cm
2)
Age-adjusted 0.96 (0.96–0.97) 0.94 (0.93–0.96)
* 0.92 (0.90–0.95)
* 0.93 (0.91–0.95)
* <0.0001
Model 1
a 0.96 (0.96–0.97) 0.94 (0.93–0.96)
* 0.92 (0.90–0.95)
* 0.94 (0.92–0.96)
* 0.0001
Model 2
b 0.96 (0.96–0.96) 0.95 (0.94–0.96)
* 0.93 (0.90–0.95)
* 0.94 (0.92–0.96) 0.0019
Femoral neck (g/cm
2)
Age-adjusted 0.79 (0.78–0.79) 0.77 (0.76–0.79)
* 0.77 (0.74–0.79) 0.76 (0.74–0.78)
* 0.0006
Model 1
a 0.79 (0.78–0.79) 0.77 (0.76–0.79)
* 0.77 (0.75–0.79) 0.77 (0.75–0.79) 0.004
Model 2
b 0.79 (0.78–0.79) 0.78 (0.77–0.79) 0.77 (0.75–0.80) 0.77 (0.76–0.79) 0.03
aAdjusted for age, clinic, BMI, and smoking
bAdjusted for age, clinic, BMI, smoking, self-reported health, alcohol (drinks per week), calcium, PASE score, coronary artery disease, stroke,
and diabetes
*p value<0.05 compared to no COPD or asthma group
1346 Osteoporos Int (2010) 21:1341–1349vertebral and hip fractures in men taking inhaled or oral
corticosteroids, the p value was not statistically significant
and was likely due to the small sample size of fractures.
Smoking is a well-known cause of chronic lung disease.
Corticosteroids, commonly prescribed to patients with
COPD or asthma, are known to reduce bone formation
and increased bone resorption [18]. Lower body weight and
decreased exercise capacity in COPD patients have been
shown to decrease bone mineral content and lean body
mass [19]. Decreased muscle strength from physical
inactivity can also accelerate respiratory decline and
negatively affect BMD. In this study, corticosteroids and
Table 4 Age-adjusted and multivariate-adjusted
a mean (95% CI) annualized percent change bone mineral density by COPD or asthma status
No COPD or asthma
(N=3654)
COPD or asthma,
no steroids
(N=294)
COPD or asthma,
oral steroids
(N=103)
COPD or asthma,
inhaled steroids
(N=177)
p trend
Total spine (g/cm
2)
Age-adjusted 0.62 (0.58, 0.66) 0.55 (0.41, 0.68) 0.72 (0.45, 0.99) 0.91 (0.72, 1.11)
* 0.03
Model 1
a 0.62 (0.58, 0.66) 0.55 (0.42, 0.68) 0.77 (0.50, 1.03) 0.92 (0.72, 1.11)
* 0.01
Model 2
b 0.62 (0.58, 0.66) 0.57 (0.44, 0.70) 0.73 (0.46, 1.00) 0.91 (0.72, 1.11)
* 0.02
Total hip (g/cm
2)
Age-adjusted −0.37 (−0.39, −0.34) −0.45 (−0.55, −0.35) −0.24 (−0.45, −0.04) −0.31 (−0.46, −0.16) 0.69
Model 1
a −0.37 (−0.40, −0.34) −0.44 (−0.53, −0.34) −0.21 (−0.42, −0.01) −0.33 (−0.48, −0.18) 0.60
Model 2
b −0.37 (−0.40, −0.34) −0.41 (−0.51, −0.31) −0.17 (−0.38, −0.03) −0.31 (−0.46, −0.16) 0.28
Femoral neck (g/cm
2)
Age-adjusted −0.35 (−0.38, −0.31) −0.30 (−0.43, −0.17) −0.26 (−0.53, −0.01) −0.33 (−0.53, −0.14) 0.53
Model 1
a −0.35 (−0.38, −0.31) −0.31 (−0.44, −0.18) −0.28 (−0.55, −0.01) −0.33 (−0.52, −0.13) 0.60
Model 2
b −0.35 (−0.39, −0.32) −0.27 (−0.40, −0.14) −0.26 (−0.53, −0.01) −0.31 (−0.50, −0.11) 0.30
aAdjusted for age, clinic, BMI, and smoking
bAdjusted for age, clinic, BMI, smoking, self-reported health, alcohol (drinks per week), calcium, PASE score, coronary artery disease, stroke,
and diabetes
*p value<0.05 compared to no COPD or asthma group
Table 5 Age-adjusted and multivariate-adjusted
a hazard rates for hip and spine and nonhip and nonspine fractures by COPD or asthma status
No COPD or asthma,
(N=4,827)
COPD or asthma, no
steroids (N=434)
COPD or asthma, oral
steroids (N=103)
COPD or asthma, inhaled
steroids (N=177)
Clinical vertebral fractures N=74 N=20 N=2 N=6
Age-adjusted 1.0 (referent) 3.17 (1.93, 5.20) 1.39 (0.34, 5.67) 2.11 (0.92, 4.85)
Model 1
a 1.0 (referent) 2.98 (1.80, 4.94) 1.35 (0.33, 5.50) 2.00 (0.87, 4.61)
Model 2
b 1.0 (referent) 2.64 (1.57, 4.44) 1.14 (0.28, 4.71) 1.86 (0.80, 4.32)
Hip fractures N=88 N=11 N=2 N=5
Age-adjusted 1.0 (referent) 1.44 (0.77, 2.70) 1.19 (0.29, 4.82) 1.43 (0.58, 3.52)
Model 1
a 1.0 (referent) 1.30 (0.68, 2.45) 1.14 (0.28, 4.63) 1.41 (0.57, 3.48)
Model 2
b 1.0 (referent) 1.09 (0.56, 2.14) 0.92 (0.22, 3.77) 1.24 (0.50, 3.09)
Clinical nonvertebral, nonhip fractures N=359 N=43 N=4 N=17
Age-adjusted 1.0 (referent) 1.40 (1.02, 1.91) 0.56 (0.21, 1.49) 1.30 (0.80, 2.11)
Model 1
a 1.0 (referent) 1.42 (1.03, 1.96) 0.56 (0.21, 1.51) 1.29 (0.79, 2.11)
Model 2
b 1.0 (referent) 1.42 (1.03, 1.96) 0.55 (0.21, 1.48) 1.28 (0.78, 2.09)
Bolded cells have p values<0.05
aAdjusted for age, clinic, BMI, and smoking
bAdjusted for age, clinic, BMI, smoking, self-reported health, alcohol (drinks per week), calcium, PASE score, coronary artery disease, stroke,
and diabetes
Osteoporos Int (2010) 21:1341–1349 1347smoking appeared to mediate most of the observed
associations and additional adjustments for possible con-
founders did not attenuate the observed results.
We hypothesized that corticosteroids, smoking, physical
inactivity, low body weight, and/or malnutrition would
have explained the lower BMD and higher rates of
osteoporosis in patients with obstructive pulmonary dis-
ease. It is unclear why men with COPD or asthma would
have lower BMD at the total spine and hip independent of
these confounders. Increased levels of systemic inflamma-
tion may be a potential mechanism to explain how
pulmonary disease may affect bone. Several studies have
demonstrated that individuals with chronic airflow limita-
tion have significantly elevated levels of C-reactive protein,
fibrinogen, leucocytes, and tumor necrosis factor alpha
[20]. Low grade systemic inflammation persists even in
nonsmoking subjects with chronic airflow limitation,
suggesting that smoking cessation does not eliminate
ongoing inflammation and that inflammation is not due to
tobacco alone [21]. Another potential mechanism could be
due to hypercapnia, which has been associated with
increased bone resorption. Dimai and colleagues showed
that lower arterial pH and higher arterial carbon dioxide
levels were correlated with lower BMD in COPD patients
[22]. Finally, hormonal levels may be another mechanism.
Hormone replacement therapy and increased circulating
estrogen levels had a protective effect on pulmonary
function in pre- and postmenopausal women [23]. Further
studies to examine whether inflammation, hypercapnia, or
sex hormones mediates the relationship between pulmonary
disease and BMD are needed.
This study had several limitations. First, ascertainment of
obstructive pulmonary disease was by self-report, and
pulmonary function was not measured by spirometry.
Therefore, we were unable to make a specific pulmonary
diagnosis (i.e., chronic bronchitis, emphysema, and asth-
ma). Duration of pulmonary disease and duration of
corticosteroid treatment was unknown; therefore, any
dose-response relationship with treatment could not be
examined. These findings apply primarily to older Cauca-
sian men and may not be generalized to other populations.
Finally, the relative independent contribution of COPD or
asthma to BMD may be small. However, when this risk
factor is examined in combination with other concomitant
osteoporosis risk factors such as glucocorticoid use, weight
loss, physical activity, vitamin D deficiency, the increased
risk of osteoporosis, and fracture may be large and
clinically relevant.
Despite these limitations, this study had many strengths
including the high rates of follow-up, careful standardized
collection of detailed covariate data, BMD collection
following rigorous quality control measures, and careful
adjudication of fracture outcomes. Medication use was
validated in the clinic and accurately recorded on the
electronic medication inventory form. The careful adjudi-
cation of medications prescribed for COPD or asthma limits
misclassification bias. Additionally, the large sample of
5,541 healthy men selected from the community without
any specific pulmonary complaints reduces the potential for
volunteer bias, which is often a problem with clinic-based
populations. This enhances generalizability and comparison
with other cohorts.
The WHO estimates that 3 million people died of COPD
in 2005 and another 80 million people have moderate to
severe COPD. Chronic obstructive pulmonary disease is
projected to become the third leading cause of death
worldwide and is a major public health concern. Therefore,
clinicians may find that a history of COPD or asthma with
or without use of corticosteroids may be a useful risk factor
to identify patients who may benefit from early diagnostic
and preventive strategies for osteoporosis.
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